Xenon Pharmaceuticals Inc. Q1 FY2026 earnings call

Ian mentioned an exceptional quarter with progress toward becoming a fully integrated neuroscience company. In March, Phase 3 XTOL2 study of azetucalner (AZK) in focal onset seizures had positive results. Focus is on NDA submission to FDA in Q3 2026, increasing AZK awareness, and exploring neuropsychiatric indications. Three phase three depression studies continue enrolling. Early stage ion channel programs like XEN1701 and XEN1120 have first in human studies planned. Chris spoke about AAN meeting data, including XTOL2 data, 48-month XTOL OLE data, NAV1.1 program in Dravet syndrome, and clinical programs in depression and pain. Darren discussed commercialization path, including engagement with HCPs, launch readiness, and payer discussions. Tucker reviewed financial results, noting successful public offering and strong balance sheet.

Anticipated NDA submission to FDA in third quarter of 2026. Base case assumption of standard review period followed by DEA scheduling with anticipated launch timing at end of 2027 or early 2028. Expecting to share top-line data from Exnova 2 in first half of 2027. Plan to complete first in human studies for XEN1701 and XEN1120 later this year and advance both programs to phase two proof of concept studies in pain.

Q: Paul Matias asked about pain programs, specifically NAV 1.7 Phase 1 program and Phase 2 plans.

A: Chris and others discussed progress in NAV 1.7 Phase 1, de-risking safety, and plans for Phase 2 acute pain proof of concept studies.

Q: Tess Romero asked about seizure freedom data comparison between AZK and XCOPRI.

A: Ian, Chris, and Darren discussed patient population differences, RR100 data, and ease of use attributes of AZK.

Q: Corey Kasimov asked if investors should anticipate data this year on pain assets.

A: Confirmed phase one healthy volunteer studies for 1701 and 1120 will complete this year.

Q: Peyton Bonsack asked about pre-MDA meetings and DEA scheduling.

A: Chris discussed pre-NDA meetings, standard review, and DEA scheduling timelines.

Q: Andrew Tsai asked about other Phase III data analysis later this year.

A: Chris discussed plans to share combined XTOL data, seizure subtypes analysis, and update XTOL OLE data at AES.

Q: Brian Scorny asked about NAV 1.1 differentiation in Dravet and pain asset long-term plans.

A: Chris discussed NAV 1.1 potential for disease modification and pain asset plans for acute and chronic pain.

Q: Miles Minter asked about commercial side and competing branded ASM.

A: Darren discussed commercial preparation, team, and brand marketing positioning.

Q: David Hong asked about leveraging balance sheet for AZK commercial launch.

A: Ian and Darren discussed early commercial preparation, team, and launch plans.

Q: Ben Burnett asked about commercialization in XUS territories.

A: Ian discussed global clinical development and plans to engage partners for XUS commercialization